American Society of Clinical Oncology - 36th Annual Meeting
1Duke University Medical Center, Box 2606, Durham, NC 27710, USA. morse004@mc.duke.edu
Abstract:
The American Society of Clinical Oncology (ASCO) 36th Annual Meeting, which took place from 20-23 May 2000 in New Orleans, was, as usual, a large, well-attended, internationally-represented meeting of cancer specialists. Both clinical trials of well established drugs for the treatment of cancer, as well as novel agents under development were presented in poster sessions, poster discussion sessions and large oral sessions. The prominent areas of new drug development presented were anti-angiogenic agents, tyrosine kinase inhibitors, immunotherapeutics and agents that modify the pharmacology or pharmacodynamics of chemotherapeutic agents. Sessions highlighting the translational development of several compounds with other mechanisms of action were also well attended. While there were no agents with unexpectedly dramatic clinical benefit, there were a number of promising developments.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:21Cancer Survival Analysis
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...